GlobeNewswire: Ascendis Pharma Contains the last 10 of 226 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T12:48:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/04/2839594/0/en/Ascendis-Pharma-to-Participate-in-the-Leerink-Partners-Global-Biopharma-Conference-2024.html?f=22&fvtc=4&fvtv=36703Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 20242024-03-04T13:30:00Z<![CDATA[COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida.]]>https://www.globenewswire.com/news-release/2024/02/07/2825539/0/en/Ascendis-Pharma-Reports-Fourth-Quarter-and-Full-Year-2023-Results.html?f=22&fvtc=4&fvtv=36703Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results2024-02-07T21:01:00Z<![CDATA[COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.]]>https://www.globenewswire.com/news-release/2024/02/07/2825181/0/en/Ascendis-Pharma-to-Participate-in-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=36703Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-07T13:30:00Z<![CDATA[COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference.]]>https://www.globenewswire.com/news-release/2024/01/31/2821563/0/en/Ascendis-Pharma-to-Report-Full-Year-2023-Financial-Results-and-Provide-Business-Update-on-February-7-2024.html?f=22&fvtc=4&fvtv=36703Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 20242024-01-31T21:15:00Z<![CDATA[COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and webcast on February 7, 2024, at 4:30 p.m. Eastern Time (ET) to discuss 2023 financial results.]]>https://www.globenewswire.com/news-release/2024/01/31/2821541/0/en/Ascendis-Pharma-Launches-2nd-TransCon-Product-YORVIPATH-Now-Available-in-Germany-and-Austria-for-Adults-with-Chronic-Hypoparathyroidism.html?f=22&fvtc=4&fvtv=36703Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism2024-01-31T21:01:00Z<![CDATA[COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria. YORVIPATH is the second product developed with Ascendis Pharma’s TransCon technology platform to be launched commercially.]]>https://www.globenewswire.com/news-release/2024/01/29/2818910/0/en/New-Company-Eyconis-Formed-to-Develop-Ascendis-Pharma-Ophthalmology-Assets-with-150-Million-Commitment-from-External-Investors.html?f=22&fvtc=4&fvtv=36703New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors2024-01-29T13:30:00Z<![CDATA[COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.]]>https://www.globenewswire.com/news-release/2024/01/07/2805023/0/en/Ascendis-Pharma-Introduces-Vision-2030.html?f=22&fvtc=4&fvtv=36703Ascendis Pharma Introduces Vision 20302024-01-07T22:45:00Z<![CDATA[COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference.]]>https://www.globenewswire.com/news-release/2023/12/28/2801855/0/en/Ascendis-Pharma-to-Participate-in-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=36703Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference2023-12-28T21:15:00Z<![CDATA[COPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President & Chief Financial Officer, and Kennett Sprogøe, Ph.D., Executive Vice President, Head of Research & Product Development, will participate in the 42nd Annual J.P. Morgan Healthcare Conference.]]>https://www.globenewswire.com/news-release/2023/12/20/2799270/0/en/Significant-Health-and-Quality-of-Life-Improvements-Achieved-in-Children-with-Achondroplasia-Treated-for-One-Year-with-TransCon-CNP-Navepegritide-at-100-%C2%B5g-kg-week.html?f=22&fvtc=4&fvtv=36703Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week2023-12-20T13:30:00Z<![CDATA[COPENHAGEN, Denmark, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new analyses from the blinded and ongoing open-label extension (OLE) portions of ACcomplisH, the Company’s Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial of TransCon CNP in children ages 2-10 years with achondroplasia. In the trial, all 57 patients have now completed one year of treatment with TransCon CNP (navepegritide) at 100 µg/kg/week, the dose agreed with regulatory agencies for the active arm in the pivotal ApproaCH Trial.]]>https://www.globenewswire.com/news-release/2023/12/19/2798534/0/en/TransCon-hGH-lonapegsomatropin-Achieved-Statistically-Superior-Outcomes-Compared-to-Placebo-in-Phase-3-foresiGHt-Trial-of-Adults-with-Growth-Hormone-Deficiency.html?f=22&fvtc=4&fvtv=36703TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency2023-12-19T13:30:00Z<![CDATA[– On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo]]>